DDInter581 DDInter1376
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dolasetron {u} (Compound) resembles {v} (Compound) Hyoscyamine
Dolasetron {u} (Compound) resembles {v} (Compound) Atropine
Dolasetron {u} (Compound) binds {v} (Gene) CYP2D6
Dolasetron {u} (Compound) upregulates {v} (Gene) UBQLN2
Dolasetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Dolasetron {u} (Compound) causes {v} (Side Effect) Oliguria
Dolasetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Dolasetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rifampicin
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxycodone
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Donepezil
Dolasetron (Compound) resembles Hyoscyamine (Compound)
Dolasetron (Compound) resembles Atropine (Compound)
Dolasetron (Compound) binds CYP2D6 (Gene)
Dolasetron (Compound) upregulates UBQLN2 (Gene)
Dolasetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Dolasetron (Compound) causes Oliguria (Side Effect)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Donepezil